Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
By R. Amara, F. Villinger, J. Altman, S. L. Lydy, S. O’Neil, S. Staprans, D. Montefiori, Yan Xu, J. G. Herndon, L. Wyatt and 12 more. Science, 2001
683 citations recorded by the source corpus.
Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.
Subfields: Epidemiology, Infectious Diseases, Virology
View Paper: https://www.semanticscholar.org/paper/d6e7ab93f48ab84d255f35ec6ca81198b805ef6e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Virology
Citations in the corpus
- Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load (2003, result): “Recent vaccine studies in the nonhuman primate model have shown encouraging results regarding attenuation of disease progression following induction of robust SIV-specific CD8-T-cell responses ( 7 , 10, 44).”
- Analysis of Total Human Immunodeficiency Virus (HIV)-Specific CD4+ and CD8+ T-Cell Responses: Relationship to Viral Load in Untreated HIV Infection (2001, background): “Moreover, recent studies have demonstrated that vaccine strategies capable of eliciting viral specific CD8 T-cell responses can control viral replication and prevent the onset of disease ( 3 , 5, 42).”